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Abstract 
Background: The diagnosis of pulmonary tuberculosis (PTB) and smear-negative pulmonary tuberculosis (SNPT) in 
resource-limited countries is often solely based on clinical signs, chest X-ray radiography and sputum smear micros-
copy. We investigated currently used methods for the routine diagnosis of SNPT in the Republic of Congo (RoC) 
among TB suspected patients. The specific case of HIV positive patients was also studied.
Methods: A cross-sectional study was conducted at the anti-tuberculosis center (CAT) of Brazzaville, RoC. Tuberculo-
sis suspects were examined for physical signs of TB. Clinical signs, results from sputum smear microscopy, tuberculin 
skin test (TST) and chest X-ray were recorded.
Results: Of the 772 enrolled participants, 372 were diagnosed PTB. Cough was a common symptom for PTB and no 
PTB patients. Pale skin, positive TST, weight loss and chest X-ray with abnormalities compatible with PTB (PTB-CXR) 
were significant indicators of PTB. Thirty-six percent of PTB patients were diagnosed SNPT. This category of patients 
presented less persistent cough and less PTB-CXR. Anorexia and asthenia were significant indicators of SNPT. In the 
case of HIV+ patients, 57 % were SNPT with anorexia, asthenia and shorter cough being strong indicators of SNPT.
Conclusion: Chest X-ray abnormalities, weight loss, pale skin and positive TST were significant indicators of PTB. 
Anorexia and asthenia showed good diagnostic performance for SNPT, which deserve to be recommended as index 
indicators of SNPT diagnosis. Duration of cough is also a relevant indicator, especially for HIV+ patients.
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Background
Tuberculosis (TB), an airborne infectious disease, is the 
second leading cause of death from an infectious disease 
worldwide, after the human immunodeficiency virus 
(HIV). In 2013, the TB disease burden estimated by World 
Health Organization (WHO) was 9 million people and 1.5 
million deaths were estimated to be caused by TB [1].
In resource-constrained settings where sputum cul-
ture and nucleic acid amplification techniques are not 
routinely available, diagnosis of pulmonary tuberculosis 
(PTB) is based on physical examination, clinical signs, 
sputum smear microscopy and chest X-ray radiogra-
phy. Sputum smear microscopy is commonly used for 
diagnosing PTB [2]. It relies on the detection of acid-
fast bacilli (AFB) by the Ziehl-Neelsen light microscopy 
method [3]. This rapid and cheap technique is known 
for having very good specificity but moderate sensitiv-
ity [4]. It is estimated that 42 % of PTB cases are smear-
negative pulmonary tuberculosis (SNPT). Although 
patients with SNPT are less infectious than patients with 
smear-positive pulmonary tuberculosis (SPPT) [5], they 
do contribute to PTB transmission and are thought to be 
responsible for approximately 20  % of TB transmission 
[6]. In addition, A good number of TB infections in Africa 
are reported as SNPT [7]. During clinical examination of 
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patients with PTB, the presence of respiratory symptoms 
[8] and general characteristic signs of TB are assessed 
[9]. In countries with limited health infrastructure, the 
diagnosis of PTB, and especially SNPT, is a challenge [10, 
11] and relies on the use of clinical algorithms. However, 
the sensitivity and specificity of these algorithms vary 
depending on the clinicians experience [12].
TB is also an opportunistic infection for HIV infected 
patients [13, 14]. The late diagnoses of HIV as well as TB 
are significant factors of high mortality in TB patients 
[15]. There is a scarcity of data on SNPT for TB and HIV 
infected individuals in the Central African region [16].
The Republic of Congo (RoC) is considered as a “high bur-
den” country for TB and HIV infections [17]. In 2013, the 
incidence of TB was 382 per 100,000 population and 10,776 
cases of TB were reported (from which 73 % of cases were 
PTB) [18]. The same year, 69,000 HIV infected people and 
5400 deaths were reported respectively [19]. We recently 
showed that TB is the leading cause of death among HIV 
infected patients in Brazzaville and that 70 % of HIV posi-
tive TB suspected patients were probably SNPT [4].
Since 2009, the Central African Network on Tubercu-
losis HIV/AIDS and Malaria (CANTAM) has conducted 
a number of baseline epidemiology studies with the aim 
of preparing sites for the conduct on clinical trials. This 
network is thus generating useful data that can be used 
to inform policy changes and health systems improve-
ments in the sub-region. The National TB Control Pro-
gram (NTCP) in the RoC is plagued by lack of resources 
in terms of prevention, diagnosis and treatment of TB. In 
order to build a case for the need of new tools and inter-
ventions for TB control, it is important to understand 
the current situation. This study thus aimed at evaluating 
current and routine methods in PTB and SNPT diagno-
sis, which, according to the NTCP guidelines, is mostly 
based on clinical signs and chest X-ray radiography. In 
addition, we addressed the diagnosis of SNPT in HIV 
infected patients [10] since delayed diagnosis in this par-
ticular population may be an important cause of mortal-
ity and morbidity.
Methods
Patient selection
A cross-sectional study with prospective enrollment 
was conducted at the anti-tuberculosis center (CAT) 
of Brazzaville, RoC, from February to June 2011. Study 
participants were male and female patients aged from 
18 to 70-years-old, who gave a written informed con-
sent to participate in the study. Ethical authorization 
was obtained in August 2010 (No. 00000067/DGRST/
CERSSA) from the institutional ethics committee Com-
ité d’Ethique pour la Recherche en Science de la Santé 
(CERSSA).
Specimen collection
Demographic data (age, sex, place of residence and occu-
pation) and clinical data were recorded for all participants 
during a medical interview and a physical examination 
by a trained clinician of the CAT. Chest radiography 
and sputum collection were performed according to the 
national algorithm against TB [20]. Participants provided 
three sputum specimens over the course of 2  days. The 
first specimen was collected the day the patient arrived at 
the CAT (day 1), the second was collected by the patient 
himself in the early morning of day 2 and the third was 
collected at the CAT when the patient brought back the 
early morning specimen (day 2).
National algorithm against tuberculosis
The national guideline against TB (Guide national de 
lutte contre la tuberculose) [20] in RoC includes screening 
for common clinical signs and symptoms such as current 
cough (if self-reported, cough >2  weeks), fever, asthe-
nia (fatigue), anorexia (loss of appetite) and pale skin. A 
tuberculin skin test (TST) and a X-ray chest radiography 
were also performed systematically [4]. Sputum samples 
were tested with the direct Ziehl-Neelsen light and fluo-
rescence microscopy methods and assessed by a trained 
technician. Abnormal chest X-ray compatible with PTB 
(termed PTB-CXR) was followed up with HIV testing to 
all consenting individuals.
Case definitions
Smear‑positive pulmonary tuberculosis (SPPT)
Patients with at least two positive sputum samples and 
clinical signs compatible with PTB were diagnosed as 
SPPT. These patients were given the standard anti-TB 
treatment according to the national guideline against TB.
Smear‑negative pulmonary tuberculosis (SNPT)
Patients with at least two sputum samples negative for 
AFB were treated with a full course of non-specific 
chemotherapy for 15 days. After this period, if there was 
no improvement of patient condition, new sputum sam-
ples were collected. If the second sputum analysis was 
still negative for AFB, a PTB-CXR was noted and clini-
cal signs were compatible with PTB, the patients were 
diagnosed as SNPT and they were given the standard 
anti-tuberculosis treatment according to the national 
guideline against TB. The diagnosing clinician’s experi-
ence plays an important role in the diagnosis of SNPT.
Statistical analysis
Quantitative variables were expressed as median with 
interquartile range (IQR). Differences among variables 
were analyzed with the χ2 or Fisher’s exact test for cat-
egorical variables. Analysis of data was performed using 
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the STATA software package (version 11, StataCorp, 
Texas, USA). For all potential predictors, unadjusted odd 
ratios (ORs) were calculated and provided along with 
their 95  % confidence intervals (95  % CIs). Multivariate 
analyses were performed to investigate any association 
between clinical factors and disease. A p value <0.05 was 
considered to be statistically significant.
Results
Study population
Among the 775 patients enrolled in this study (Fig. 1), 372 
(48 %) and 367 (47 %) were diagnosed with PTB and with 
no PTB respectively. Thirty-six out of the 775 patients 
(5 %) were excluded because of missing data. None of the 
recruited patients received previous TB treatment. Two 
hundred and twenty PTB patients (60 %) were male and 
the median age was 32-years-old (Table 1).
Diagnosis of PTB and SNPT
In addition to demographical data, clinical signs (cough, 
fever, anorexia, asthenia, pale skin, weight loss) and 
results of TST and CXR examinations were evaluated in 
their suitability in PTB and SNPT diagnosis.
Cough was common to all PTB cases and to 98  % of 
the no PTB cases, as would be expected, since this 
symptom is the major reason for consultation at the 
CAT. Fever, anorexia and asthenia were not indicators 
of PTB. However, pale skin, positive TST and weight 
loss were significant indicators of PTB with OR of 2.88, 
1.79 and 5.75 respectively (Table 1). Multivariate analy-
sis showed that patients with pale skin, positive TST 
and weight loss were 2.76 times more likely to be SNPT 
cases (OR of 2.76; 95 % CI 1.57–4.86; R2 = 0.504). PTB-
CXR was found in 93 % of the PTB patients and never 
in the no PTB patients. PTB patients were split into 
SPPT and SNPT groups based on the sputum smear 
assay (Table  2). Out of the 372 PTB cases, 132 (36  %) 
were diagnosed SNPT after clinical, radiology and spu-
tum smear examinations. SNPT cases had less persistent 
cough that lasted more than 14 days (OR 0.39; 95 % CI 
0.19–0.82) and presented less PTB-CXR (0.18; 95  % CI 
0.07–0.44).
On the opposite, patients with anorexia and asthenia 
had significantly elevated risk for SNPT with OR of 2.75; 
95 % CI 1.47–5.14 and 2.65; 95 % CI 1.13–6.19 (Table 2). 
Multivariate analysis showed that patients with anorexia, 
asthenia and a shorter cough were 2.37 times more likely 
to be diagnosed SNPT (OR of 2.37; 95  % CI 1.15–4.87; 
R2 = 0.355).
Diagnosis of SNPT for HIV positive patients
Eighty-eight (24  %) PTB patients presented a positive 
HIV serology (Fig.  2) and were investigated in more 
details. Performances of putative indicators regarding the 
prediction of SNPT cases are presented in Table 3. Fifty-
seven percent of PTB/HIV+ patients were diagnosed as 
SNPT. The median duration of cough was the same for 
both SPPT and SNPT groups (30  days). However, the 
IQR was opposed as shown by the distribution of dura-
tion of cough in Fig.  3. SPPT patients had longer dura-
tion of cough as compared to SNPT cases. SNPT/HIV+ 
patients were eight times more likely to have anorexia 
and nine times more likely to have asthenia (OR 8.57; 
95 % CI 1.75–41.9 and OR 9.19; 95 % CI 1.06–79.93). In 
36 (5%) cases with 
incomplete or missing data
240 (64%) cases 
with SPPT
132 (36%) cases 
with SNPT
38 (43%) cases
with SPPT
50 (57%) cases 
with SNPT
367 (47%) cases with no 
pulmonary tuberculosis
Number of patients TB suspected cases 
clinical symptoms   = 775
372 (48%) cases with 
pulmonary tuberculosis
88 (24%) cases with 
HIV+/ pulmonary 
tuberculosis
HIV testing
Fig. 1 Case distribution flowchart of patients recruited at the Centre Anti-Tuberculeux in Brazzaville, Republic of Congo
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addition, SNPT/HIV+ cases were 20 times less likely to 
present an abnormal chest X-ray compatible with PTB.
Discussion
As in many developing countries, the diagnosis of PTB in 
the RoC relies on clinical symptoms examination, radi-
ography and sputum smear microscopy. In a country 
with such a resource-limited health system, faster and 
more reliable methods such as automated liquid culture 
and nucleic acid amplification are not readily available. 
Also, in the RoC, where the burden of HIV and TB are 
high, SNPT cases are expected to be more frequent [21]. 
Patients diagnosed with SNPT are thought to be less 
infectious than those with SPPT; nevertheless, they are 
still able to transmit PTB [22]. The 2010 WHO guide-
lines recommend chest radiography (CXR) as the first 
step for cases suspected of TB having negative sputum 
smears. However, it ought to be noticed that diagnosis 
cannot solely rely on CXR as the quality of this exam is 
often compromised by poor film quality and variability in 
interpretation, particularly in HIV positive patients [23].
This study showed that pale skin, positive TST, weight 
loss and abnormal CXR were good indicators of PTB. 
Consistent with previous studies, 35  % of PTB patients 
were diagnosed with SNPT [24]. SNPT cases were more 
likely to show symptoms of anorexia and asthenia. A 
cough lasting more than 2 weeks was more prevalent in 
SPPT as seen in the literature [25]. On the opposite, a 
cough lasting less than 2 weeks could be symptomatic of 
SNPT. This led the WHO to change their recommenda-
tion for TB evaluation to include a cough of any duration 
replacing the previously conventional criteria of a persis-
tent cough lasting more than 2 weeks [26]. Other clinical 
symptoms recommended by WHO include, hemoptysis 
(blood in sputum) and dyspnea (breathlessness)—and 
non-respiratory symptoms—such as chest pain, fever, 
chills, night sweats, anorexia, asthenia, and weight loss. 
These signs are somewhat ubiquitous in a clinical setting, 
thereby non-specific, and could possibly indicate a mul-
titude of other illnesses which will confuse diagnosis of 
SNPT in countries such as RoC with limited options for 
fast, accurate and sensitive diagnostic methods.
Table 1 Potential predictors for pulmonary tuberculosis in TB suspect individuals
N number of TB suspects in the group, NA not applicable
Characteristics PTB,  
N = 372
no PTB,  
N = 367
Unadjusted OR  
(95 % CI)
LR R2 P value
Men (%) 220 (59) 191 (52) 1.33 (0.99–1.77) 3.77 0.004 0.052
Median age (years) (IQR) 32 (24–42) 34 (25–46) 0.98 (0.97–0.99) 4.68 0.031 0.032
Cough (%) 372 (100) 359 (98) NA NA NA 0.004
Fever (%) 338 (91) 321 (88) 1.42 (0.89–2.28) 2.21 0.002 0.139
Anorexia (%) 299 (80) 298 (81) 0.95 (0.66–1.37) 0.08 0.0001 0.777
Asthenia (%) 334 (90) 314 (86) 1.48 (0.95–2.31) 3.07 0.003 0.082
Pale skin (%) 53 (14) 20 (5) 2.88 (1.69–4.93) 16.62 0.016 <0.001
Weight loss (%) 360 (97) 308 (84) 5.75 (3.03–10.89) 37.93 0.037 <0.001
Positive TST (%) 283 (76) 235 (64) 1.79 (1.30–2.46) 12.84 0.013 <0.001
PTB-CXR (%) 346 (93) 0 (0) NA NA NA <0.001
Table 2 Potential predictors for SNPT in PTB patients
N number of patients in the group
Characteristics SPPT,  
N = 240
SNPT,  
N = 132
Unadjusted OR  
(95 % CI)
LR R2 P value
Duration of cough above 14 days (%) 226 (94) 114 (86) 0.39 (0.19–0.82) 6.28 0.013 0.012
Median of duration of cough (days) (IQR) 30 (29–61) 30 (21–60) 0.99 (0.98–1.00) 3.37 0.007 0.080
Fever (%) 215 (90) 123 (93) 1.59 (0.72–3.51) 1.38 0.003 0.253
Anorexia (%) 181 (75) 118 (89) 2.75 (1.47–5.14) 11.40 0.024 0.002
Asthenia (%) 209 (87) 125 (95) 2.65 (1.13–6.19) 5.92 0.015 0.025
Pale skin (%) 32 (13) 21 (16) 1.23 (0.68–2.23) 0.46 0.001 0.497
Weight loss (%) 233 (97) 127 (96) 0.76 (0.24–2.45) 0.20 0.0004 0.650
Positive TST (%) 183 (76) 100 (76) 0.97 (0.59–1.60) 0.01 0.000 0.915
PTB-CXR (%) 233 (97) 113 (86) 0.18 (0.07–0.44) 16.44 0.034 <0.01
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We found that anorexia, asthenia and shorter dura-
tion cough were significantly identified in HIV infected 
patients with SNPT. In 2013, the WHO published guide-
lines for intensified case-finding in people living with 
HIV which took into account HIV status, AIDS severity 
and early CXR diagnosis in resource limited settings with 
high HIV/TB burden [26, 27]. Although CXR examina-
tion is an important component of SNPT diagnosis, it 
should be noted that its reliability can be affected by the 
HIV infection itself.
The results of this study hence confirm the need to 
propagate the use of improved point of diagnostics such 
as the Xpert MTB/RIF assay [28] which is based on 
nucleic acid amplification technique that detect the DNA 
of Mycobacterium tuberculosis and genetic mutations 
associated with resistance to the drug Rifampicin. From 
Number of patients TB suspected, who 
accepted to participate to HIV test = 425
Number of patients TB suspected 
HIV uninfected = 292
Number of patients TB suspected cases 
clinical symptoms   = 775
Number of patients TB 
suspected, HIV infected= 133
45(33.8%) cases with HIV +/ 
no pulmonary tuberculosis
88 (66.2%) cases with HIV+/
pulmonary tuberculosis
50 (57%) cases with 
SNPT
38 (43%) cases 
with SPPT
HIV testing
Fig. 2 Case distribution flowchart of HIV infected patients recruited at the Centre Anti-Tuberculeux in Brazzaville, Republic of Congo
Table 3 Potential predictors for pulmonary tuberculosis in HIV infected patients
N number of suspects in the group, NA not applicable
Characteristics SPPT,  
N = 38
SNPT,  
N = 50
Unadjusted OR  
(95 % CI)
LR R2 P value
Men (%) 19 (50) 19 (38) 0.61 (0.26–1.44) 1.27 0.011 0.262
Median age, years (IQR) 37.5 (29–44) 39 (29–44) 1.02 (0.98–1.07) 1.11 0.0093 0.296
Median duration of cough (days) (IQR) 30 (30–60) 30 (15–31) 0.99 (0.97–1.01) 1.11 0.0092 0.323
Fever (%) 34 (90) 46 (92) 1.35 (0.32–5.79) 0.17 0.0014 0.684
Anorexia (%) 28 (74) 48 (96) 8.57 (1.75–41.9) 9.51 0.079 0.008
Asthenia (%) 32 (84) 49 (98) 9.19 (1.06–79.93) 5.92 0.049 0.045
Pale skin (%) 9 (24) 11 (22) 0.91 (0.33–2.48) 0.03 0.0003 0.852
Weight loss (%) 37 (97) 50 (100) NA NA NA NA
Positive TST(%) 25 (66) 39 (78) 1.84 (0.72–4.75) 1.61 0.013 0.203
PTB-CXR (%) 35 (92) 32 (64) 0.15 (0.04–0.57) 10.38 0.086 0.005
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a single sputum sample, the result is obtained within 2 h. 
Since December 2010, WHO endorsed the Xpert MTB/
RIF technology [29] with the expectation of earlier diag-
nosis and treatment initiation [30]. Unfortunately, only 
one Xpert MTB/RIF device is available in RoC [18]. In 
this country, only 2 % of the new TB cases were tested for 
multidrug resistance (MDR) and 17 % of tested patients 
were MDR-TB confirmed cases [18] which demon-
strate the need for this technology. The national guide-
lines for Tuberculosis control in RoC recommend the 
use of Rifampicin and Isoniazid drugs (together with 
Ethambutol and Pyrazinamid) to treat new TB patients. 
Since Xpert MTB/RIF assay can test for resistance to 
Rifampicin, it should be routinely used in RoC to bet-
ter diagnose TB and offer a better treatment to patients, 
especially for those having confirmed resistance to 
Rifampicin.
Recently, the use of the lateral flow urine TB lipoara-
binomannan (LAM) antigen test (urine TB-LAM test for 
HIV infected patients was recommended in Uganda [31]. 
This rapid point-of-care test showed good performance 
in HIV-infected patients with advanced immune-sup-
pression [32]. Such rapid diagnosis tools in HIV prevalent 
settings increases the ability to quickly identify patients 
who are at higher risk for death.
Conclusion
A number of diagnosis tools can play an important role 
in finding SNPT cases. In a high TB and HIV prevalence 
setting, where culture and nucleic acid amplification 
technique are not routinely available, clinical signs and 
inexpensive examinations such as sputum smear micros-
copy, TST and chest X-ray radiography are of major 
interest in the diagnosis of PTB. However, it is necessary 
for the diagnosis to be done in a rigorous, quick and sys-
tematic manner since these signs are also indicative of 
a number of other diseases. Anorexia, asthenia and less 
persistent cough are good predictors of SNTP. These 
symptoms thus deserve to be recommended as indica-
tors of SNPT diagnosis in country-level TB dispensaries 
in RoC. Morbidity and mortality associated with delayed 
diagnosis may be reduced with this strategy. These indi-
cators are significantly of greater importance for HIV 
infected patients. In order to minimize over- and under-
diagnosis of PTB, the use of diagnostic tools such as 
Xpert MTB/RIF assay and urine TB-LAM test should be 
expanded within the country.
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